Replies to post #171816 on Biotech Values

[DewDiligence]

If the CVR does not trade and does not have an ascertainable value, there is an argument that you can defer recognition. The Sanofi-Aventis disclosure [in the Genzyme deal] took the position that the receipt of the CVR was taxable, but that the subsequent tax consequences are unclear.

Thanks. I figured this would be a gray area, LOL.